Banka Bioloo NSE SME IPO Review (Avoid)

Review By on January 31, 2018

Banka Bioloo Ltd. (BBL) is focusing on giving sanitation solutions to those who do not have access to toilets as well as to those who have toilets but face trouble treating and managing waste. BBL aims to provide sanitation infrastructure and hygienic solutions for human waste treatment and disposal. Currently it provides sanitation services to Indian Railways and corporate entities. Its bio-digester technology is patented by DRDO (Defense Research and Development Organization). It has installed over 6000 bio-toilet units across India and currently undertake 12 O & M service contracts with Indian Railways.

To part finance its capital expenditure at its Aler and Ibrahimpatnam units, working capital and general corpus fund needs, BBL is coming out with a maiden IPO of 1098000 equity shares of Rs. 10 each at a fixed price of Rs. 115 per share to mobilize Rs. 12.63 cr. Issue opens for subscription on 05.02.18 and will close on 07.02.18. Minimum application is to be made for 1200 shares and in multiples thereon, thereafter. Post allotment, shares will be listed on NSE SME Emerge. Issue is solely lead managed by Aryaman Financial Services Ltd. and Bigshare Services Pvt. Ltd. is the registrar to the issue. Issue constitutes 26.7% of the post issue paid up capital of the company. Average cost of acquisition of shares by the promoters is Rs. 1.63 per share. After initial equity raising at par, it raised further equity in the price range of Rs. 500 to Rs. 1079 per share between March 2013 and March 2015. It has also issued bonus shares in the ratio of 23 for 1 in October 2017. Post issue its current paid up equity capital of Rs. 3.01 cr. will stand enhanced to Rs. 4.11 cr.

On performance front, BBL has posted turnover/net profits of Rs. 5.30 cr. / Rs. 0.09 cr. (FY14), Rs. 8.20 cr. / Rs. 0.08 cr. (FY15), Rs. 14.33 cr. / Rs. 0.32 cr. (FY16) and Rs. 15.16 cr. / Rs. 1.16 cr. (FY17). For first half of current fiscal, it has reported net profit of Rs. 0.32 cr. on a turnover of Rs. 5.67 cr. It appears that for FY17 inventory adjustment has resulted in improved profits. For last three fiscals, it has posted an average EPS of Rs. 2.32 and an average RoNW of 18.82% on an equity base of Rs. 0.13 crore that will enhance many fold now. Issue is priced at a P/BV of 0.34 on the basis of its NAV of Rs. 342.30 as on 30.09.17 and at a P/BV of 2.79 on the basis of its post issue NAV of Rs. 41.16. If we annualize latest earnings and attribute it to fully diluted post issue equity, then asking price is at a P/E of around 74 making it exorbitantly priced offer. It has no listed peers to compare with.

On merchant banker’s front, this is the 26th mandate from its stable in last three fiscals. Out of last 10 listings, 2 opened at discount, 3 around par and the rest with a premium ranging from 1% to 73%. 73% premium was from Apollo Micro the only main board IPO from Aryaman in last thee fiscals.


Conclusion / Investment Strategy

Although company is in a lucrative business as it is promoting “Swachcha Bharat”, its exorbitant pricing makes it an expensive offer. There is no harm in giving it a miss.

Reviewer recommends Avoid to the issue.

Review By on January 31, 2018

About Dilip Davda

Dilip Davda, SEBI Registered Research Analyst

Dilip Davda is a veteran financial journalist associated with the Indian stock market since 1978. He has been contributing to print and electronic media on capital markets, insurance, and finance since 1985.

He is widely recognized for reviewing public issues and non-convertible debentures (NCDs) in the primary market. Drawing on over three decades of market experience and close interaction with merchant bankers, his reviews focus on detailed fundamental and financial analysis of companies, with a special emphasis on SME public issues.

Dilip Davda

SEBI Registered Research Analyst – Mumbai

Registration No.: INH000003127 (Perpetual)

Email: dilip_davda@rediffmail.com


Disclaimer: The information provided herein is solely for educational and informational purposes and does not constitute an offer, solicitation, or recommendation to buy or sell any securities. Readers are advised to consult a qualified financial advisor before making any investment decisions. Investments in the securities market are subject to market risks. The author does not intend to invest in the securities discussed.

Banka BioLoo IPO FAQs

The initial public offer (IPO) of Banka BioLoo Ltd. offers an early investment opportunity in Banka BioLoo Ltd.. A stock market investor can buy Banka BioLoo IPO shares by applying in IPO before Banka BioLoo Ltd. shares get listed at the stock exchanges. An investor could invest in Banka BioLoo IPO for short term listing gain or a long term.

Read the Banka BioLoo IPO recommendations by the leading analyst and leading stock brokers.

Banka BioLoo IPO offers an opportunity to buy IPO shares before they get listed at the stock exchanges. Read the Banka BioLoo IPO Notes, Analysis and Recommendations by leading stock brokerage firms and experts mentioned in the above answer to "How is Banka BioLoo IPO?"

Our recommendation for Banka BioLoo IPO is to avoid.

As per the analysis by our lead analyst Mr. Dilip Davda, we suggest you to avoid the Banka BioLoo IPO.

The Banka BioLoo IPO allotment status will be available on or around February 12, 2018. The allotted shares will be credited in demat account by February 15, 2018. Visit Banka BioLoo IPO allotment status to check.

The Banka BioLoo IPO will list on Tuesday, February 27, 2018.

Read more about Banka BioLoo IPO